Over the past week IBM Life Sciences has made several big announcements that reflect a growing focus in the medtech space, including partnerships with Illumina Inc. and US FDA. The company also recently became a member of AdvaMed's newly established Digital Health section, setting up the hallowed technology firm to play a more active role in lobbying in the medical device sector.
On Jan. 9, IBM and Illumina announced a partnership to use the IBM Watson Health machine learning tool to analyze and interpret genomic data from Illumina’s TruSight Tumor 170 solid...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?